Article

Immuron (NASDAQ:IMRN) reported record first-half sales for Travelan®, achieving a 5% year-over-year increase in global revenue to AUD$4.2 million, with significant contributions from Australia and the U.S. The company also launched ProIBS®, a medical device for irritable bowel syndrome, in Australia and is preparing for further commercial expansion while awaiting clinical results for its military-grade diarrhea prevention treatments funded by the U.S. Department of Defense.